Flufenamic Acid
CAS: 530-78-9
Category: NSAIDs
| Purity | Reagent Grade ≥96%, Standard Grade ≥97%, High-Purity Grade ≥98%, Pharmaceutical Grade ≥98.0–102.0% |
| Molecular Formula | C14H10F3NO2 |
| Molecular Weight | 281.23 |
| Appearance | White to pale cream or pale yellow crystalline powder |
| Packaging | 100 mg/glass vial, 250 mg/glass vial, 500 mg/glass vial, 1 g/glass vial, 5 g/glass vial, 25 g/HDPE bottle, 100 g/HDPE bottle, or 1 kg/aluminum foil bag |
| Testing Indicators | Appearance — Visual inspection (white to pale cream or pale yellow crystalline powder); Melting point — Capillary method (125–139°C, literature range; 129–131°C, bio-fount; 134.5–135°C, ChemicalBook; 132–135°C, leyan); Boiling point — Distillation (373.9±42.0°C at 760 mmHg, predicted); Density — Hydrometer (1.47 g/cm³, ChemicalBook; 1.4±0.1 g/cm³, bio-fount); Refractive index — Not typically measured for solids; Vapor pressure — 0.0038 mmHg at 101°C (ChemicalBook); Purity — HPLC-UV or GC-FID (≥96–99.5%, C18 column for HPLC or non-polar column for GC, λ=220–286 nm); Related substances — HPLC or GC (impurity profiling including 3-trifluoromethylaniline, 2-chlorobenzoic acid, and other synthesis-related impurities); Assay — Silylated GC (≥96.0%) or aqueous acid-base titration (96.0–104.0%, Thermo Fisher specification); Loss on drying — Gravimetric (≤0.5%); Residue on ignition — Gravimetric (≤0.1%); Heavy metals — Colorimetric/ICP-MS (≤20 ppm); Identification — FTIR (characteristic peaks: N–H (aniline) ~3300–3500 cm⁻¹, O–H (carboxylic acid) ~2500–3300 cm⁻¹ broad, aromatic C–H ~3000–3100 cm⁻¹, C=O (carboxylic acid) ~1680–1720 cm⁻¹, aromatic C=C ~1600 cm⁻¹, C–F ~1100–1300 cm⁻¹, C–N ~1300–1350 cm⁻¹); UV spectrophotometry (λmax ~286 nm in methanol); ¹H NMR (DMSO-d₆: δ 6.50–7.80 ppm multiplet aromatic protons, δ 10.50 ppm broad singlet N–H, δ 12.80 ppm broad singlet COOH); ¹³C NMR (DMSO-d₆: δ 115–150 ppm aromatic carbons, δ 168 ppm carboxylic acid C=O); Mass spectrometry — EI-MS (m/z 281 [M]⁺, m/z 244 [M–Cl]⁺ equivalent fragment, m/z 196 [anthranilic acid fragment]⁺); Water content — Karl Fischer titration (GB/T 6283/EP 2.5.12); pH — Potentiometry (saturated aqueous solution, weakly acidic, pKa ~3.65); Specific optical rotation — Not applicable (achiral compound); Partition coefficient — Shake-flask method (LogP ~4.67, ChemicalBook). |
| Storage Notes | Store in a cool, dry, well-ventilated area at room temperature (15–30°C) or 2–8°C. Protect from light, moisture, and air. Keep container tightly sealed. Store powder at -20°C for long-term stability (up to 3 years); at 4°C for 2 years. In solvent, store at -80°C for 1 year or at -20°C for 6 months. Light-sensitive and air-sensitive material; avoid prolonged exposure to light and humid conditions. Some suppliers recommend storage under inert gas (nitrogen or argon) due to air sensitivity. Store away from strong oxidizing agents and incompatible substances. |
| Lead Time | 10 days |
Flufenamic Acid (INN, also known as N-(3-trifluoromethylphenyl)anthranilic acid, Arlef, Ansatin, Sastridex, or Tecramine) is a non-steroidal anti-inflammatory drug (NSAID) of the fenamic acid class. It functions as a non-selective cyclooxygenase (COX) inhibitor that reduces prostaglandin synthesis to exert anti-inflammatory, analgesic, antipyretic, and anti-rheumatic effects. It also exhibits potent ion channel modulatory activity, including inhibition of calcium-activated chloride channels (CaCCs), transient receptor potential canonical 3 (TRPC3) and TRPC7 channels, voltage-gated sodium channels, and gap junctions, while potentiating TREK1 (KCNK2) potassium channel activity. Additionally, it inhibits human transthyretin amyloid fibril formation and aldo-keto reductase family 1 members (AKR1C1/1C2/1C3). Used as a pharmaceutical intermediate and active pharmaceutical ingredient (API) for the development and quality control of oral and topical formulations. Approved for clinical use in the treatment of mild to moderate pain of musculoskeletal, joint, and soft-tissue origin, including chronic polyarthritis. Also employed in analytical method development, pharmacological research on ion channels, forced degradation studies, and quality control applications. ATC code: M01AG03.